EUVIMEDEUVIMED entdecken
Open Access

BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling

Shasha Yin iD, Charles Brobbey, Lauren E Ball iD, Tianmin Fu iD, Daniel J Sprague iD, Wenjian Gan iD

Science Advances · 2025

DOI: 10.1126/sciadv.ads6385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Shasha Yin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Proto-Oncogene Proteins c-akt, Arginine, Signal Transduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIDDK NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recognition of methylarginine marks by effector proteins (“readers”) is a critical link between arginine methylation and various cellular processes. Recently, we identified methylation of AKT1 at arginine-391 (R391), but the reader for this methylation has yet to be characterized. Here, we show that bromodomain-containing protein 9 (BRD9), a reader of acetylated lysine, unexpectedly recognizes methylated R391 of AKT1 through an aromatic cage in its bromodomain. Disrupting the methylarginine reader function of BRD9 suppresses AKT activation and tumorigenesis. RNA sequencing data show that BRD9 and AKT coregulate a hallmark transcriptional program in part through enhancer of zeste homolog 2 (EZH2)–mediated methylation of histone-3 lysine-27. We also find that inhibitors of BRD9 and EZH2 display synergistic effects on suppression of cell proliferation and tumor growth. Collectively, our study reveals a previously unknown function of BRD9 and a potential therapeutic strategy for cancer treatment by combining BRD9 and EZH2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinProto-Oncogene Proteins c-aktArginineSignal TransductionTranscription FactorsHumansMethylationAnimalsMiceCell ProliferationCell Line, TumorHistonesBromodomain Containing Proteins

Substanzen

Enhancer of Zeste Homolog 2 ProteinProto-Oncogene Proteins c-aktArginineTranscription FactorsBRD9 protein, humanEZH2 protein, humanHistonesBromodomain Containing Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Department of Biological Chemistry and Pharmacology, Center for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.

ORCID-Profile: Shasha Yin, Lauren E Ball, Tianmin Fu, Daniel J Sprague, Wenjian Gan

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Yin, S., Brobbey, C., Ball, L. E., Fu, T., Sprague, D. J., & Gan, W. (2025). BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. Science Advances. https://doi.org/10.1126/sciadv.ads6385

Vancouver

Yin S, Brobbey C, Ball LE, Fu T, Sprague DJ, Gan W. BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. Science Advances. 2025. doi:10.1126/sciadv.ads6385

BibTeX
@article{Yin2025,
  author = {Yin, Shasha and Brobbey, Charles and Ball, Lauren E and Fu, Tianmin and Sprague, Daniel J and Gan, Wenjian},
  title = {BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.ads6385}
}
Kostenlos starten →